Navigation Links
Oncolytics Biotech Inc. Announces U.S. Phase 2 Combination Clinical Trial for Non-Small Cell Lung Cancer Patients with K-RAS or EGFR-Activated Tumours
Date:9/1/2008

CALGARY, Sept. 2 /PRNewswire-FirstCall/ - Oncolytics Biotech Inc. ("Oncolytics") (TSX:ONC, NASDAQ:ONCY) announced today that following U.S. Food and Drug Administration (FDA) review, the Company is initiating a U.S. Phase 2 clinical trial using intravenous administration of REOLYSIN(R) in combination with paclitaxel and carboplatin in patients with non-small cell lung cancer (NSCLC) with K-RAS or EGFR-activated tumours. The Principal Investigator is Dr. Miguel Villalona-Calero, Professor Division of Hematology/Oncology and Department of Internal Medicine and Pharmacology at The Ohio State University Comprehensive Cancer Center.

"In this era of personalized cancer treatment, we are quite excited about this trial," said Dr. Villalona-Calero. "Although we have had for some time treatments that target EGFR, K-RAS has been an elusive target. REOLYSIN(R) has the potential to target K-RAS activated tumors, possibly enhancing the beneficial effects produced by chemotherapy."

"This trial gives Oncolytics the opportunity to treat NSCLC patients in a first-line clinical setting," said Dr. Brad Thompson, President and CEO of Oncolytics. "Assuming we achieve an acceptable response rate, the combination of REOLYSIN(R) with paclitaxel and carboplatin for NSCLC would be a strong candidate for registration studies."

This trial is a single arm, two-stage, open-label, Phase 2 study of REOLYSIN(R) given intravenously with paclitaxel and carboplatin every 3 weeks. Patients will receive four to six cycles of paclitaxel and carboplatin in conjunction with REOLYSIN(R), at which time REOLYSIN(R) may be continued as a monotherapy. It is anticipated that up to 36 patients will be treated in this trial.

Eligible patients include those with metastatic or recurrent NSCLC with K-RAS or EGFR-activated tumours, who have not received chemotherapy treatment for their metastatic or recurrent disease. Patients must have demonstrated mutations in K-RAS or EGFR, or EGFR
'/>"/>

SOURCE Oncolytics Biotech Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Oncolytics Biotech Inc. Announces Issuance of 23rd U.S. Patent
2. Oncolytics Biotech Inc. Reports Positive Interim Results of U.K. Phase Ia/Ib Combination REOLYSIN(R) and Radiation Clinical Trial
3. Media Advisory - Oncolytics Biotech Inc. to Present at BioPartnering Europe
4. Media Advisory - Oncolytics Biotech Inc. to Present at BIO InvestorForum 2007
5. Oncolytics Biotech Inc. Announces Approval for U.K. Clinical Trial Investigating REOLYSIN(R) in Combination with Cyclophosphamide
6. Oncolytics Biotech Inc. Collaborators to Present Positive Interim Results of U.K. Phase Ia/Ib Combination REOLYSIN(R) and Radiation Clinical Trial
7. Oncolytics Biotech Inc. Announces 2007 Third Quarter Results
8. Media Advisory - Oncolytics Biotech Inc. to Present at Acumen BioFin Rodman & Renshaw 9th Annual Healthcare Conference
9. Media Advisory - Oncolytics Biotech Inc. to Present at Toronto CFA Society
10. Oncolytics Biotech Inc. Announces Issuance of 24th U.S. Patent
11. Oncolytics Biotech Inc. to Present at Annual Vaccine Production Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/21/2014)... Researchers at the University of Basel in Switzerland ... of a charged molecule for the first time. ... precise measurements of molecular properties and may also ... quantum technology. The results were published in the ... the study of the interaction between matter and ...
(Date:9/20/2014)... Massachusetts, USA (PRWEB) September 20, 2014 ... prestigious 2015 Prism Awards for Photonics Innovation . ... from the multi-billion dollar optics and photonics industry, and ... optics and photonics , and Photonics Media . ... as the versatility of photonics, said SPIE CEO Eugene ...
(Date:9/19/2014)... BRISBANE, Calif., Sept. 19, 2014  InterMune, Inc. (Nasdaq: ... into a Memorandum of Understanding to settle the litigation ... Agreement and Plan of Merger dated as of August ... and InterMune, Inc.  As one term of the Memorandum ... disclosures set forth in the attached exhibit reflecting the ...
(Date:9/19/2014)... rather than electricity, to move data would consume ... a growing concern as chips, transistor counts rise. ... circuits light emitters, modulators, and detectors ... light source for optical chips is molybdenum disulfide ... as a single, atom-thick layer. Other experimental on-chip ...
Breaking Biology Technology:Uncovering the forbidden side of molecules 2Entry deadline is 10 October for international photonics Prism Awards 2Entry deadline is 10 October for international photonics Prism Awards 3Entry deadline is 10 October for international photonics Prism Awards 4InterMune Reports Memorandum of Understanding in Connection with Consolidated Delaware Action 2InterMune Reports Memorandum of Understanding in Connection with Consolidated Delaware Action 3InterMune Reports Memorandum of Understanding in Connection with Consolidated Delaware Action 4InterMune Reports Memorandum of Understanding in Connection with Consolidated Delaware Action 5InterMune Reports Memorandum of Understanding in Connection with Consolidated Delaware Action 6InterMune Reports Memorandum of Understanding in Connection with Consolidated Delaware Action 7InterMune Reports Memorandum of Understanding in Connection with Consolidated Delaware Action 8InterMune Reports Memorandum of Understanding in Connection with Consolidated Delaware Action 9InterMune Reports Memorandum of Understanding in Connection with Consolidated Delaware Action 10InterMune Reports Memorandum of Understanding in Connection with Consolidated Delaware Action 11InterMune Reports Memorandum of Understanding in Connection with Consolidated Delaware Action 12InterMune Reports Memorandum of Understanding in Connection with Consolidated Delaware Action 13InterMune Reports Memorandum of Understanding in Connection with Consolidated Delaware Action 14InterMune Reports Memorandum of Understanding in Connection with Consolidated Delaware Action 15InterMune Reports Memorandum of Understanding in Connection with Consolidated Delaware Action 16InterMune Reports Memorandum of Understanding in Connection with Consolidated Delaware Action 17InterMune Reports Memorandum of Understanding in Connection with Consolidated Delaware Action 18InterMune Reports Memorandum of Understanding in Connection with Consolidated Delaware Action 19Toward optical chips 2Toward optical chips 3
... May 14, 2012 Regenerative Sciences, Inc., a ... adult stem cell procedures, today announced that it ... and businessman John C. Malone, PhD, chairman of ... Sciences, clinical and lab-based stem cell research, the ...
... 14, 2012 /PRNewswire-iReach/ -- Functional ... is a Grand Challenges Explorations winner, an ... Foundation . Functional Circulation CEO John Brassil and colleagues ... project titled "Smart Bowl Conveys Cassava to Market with ...
... match. , Conceived at Nanyang Technological University (NTU), it comes ... that attracts bacteria and kills them without the need for antibiotics. ... cent of the bacteria and fungi that it comes in contact ... manufacturer and a company specialising in animal care products. ...
Cached Biology Technology:Regenerative Sciences Receives $2M Investment for Orthopedic Stem Cell Initiatives 2Functional Circulation LLC Receives Grand Challenges Explorations Grant for Groundbreaking Research in Global Health and Development 2Functional Circulation LLC Receives Grand Challenges Explorations Grant for Groundbreaking Research in Global Health and Development 3NTU scientists invent superbug killers 2NTU scientists invent superbug killers 3
(Date:9/21/2014)... the University of California, San Diego, have developed a ... control the activity of genes based on sequences of ... its application to human embryonic cells in a paper ... , "All of our cells have the same blueprint, ... John Whitaker, lead author of the report. "Skin cells ...
(Date:9/21/2014)... was previously thought, newborn immune T cells may have ... according to a new study led by King,s College ... that of adults, babies may still be able to ... in the journal Nature Medicine . , Our ... of immune cells, including neutrophils which play an important ...
(Date:9/21/2014)... a protein therapy that disrupts the process that causes ... travel through the blood stream and start aggressive new ... as metastasis, can cause cancer to spread with deadly ... to cancer fall prey to metastatic forms of the ... who describes a new therapeutic approach in Nature ...
Breaking Biology News(10 mins):Program predicts placement of chemical tags that control gene activity 2Immune system of newborn babies is stronger than previously thought 2Stanford researchers create 'evolved' protein that may stop cancer from spreading 2Stanford researchers create 'evolved' protein that may stop cancer from spreading 3Stanford researchers create 'evolved' protein that may stop cancer from spreading 4
... leveraged as security foundation for machine readable travel ... ... of,State decided to move to digital passports -- also known as ePassports ... to these credentials, and it turned to Entrust, Inc. (Nasdaq:,ENTU) to provide ...
... in every 500 to 650 baby boys is born with ... that until a few years ago was thought to result ... the case. A recent conference hosted by NewYork-Presbyterian Hospital/Weill Cornell ... of the condition and the recent availability of treatments for ...
... research team led by Dr. Pierre Moffatt of the ... Department of Human Genetics has uncovered the molecular mechanism ... a discovery that may have important implications for people ... findings appear in the December 14 edition of the ...
Cached Biology News:Entrust Digital Signatures Help Secure More Than 18 Million U.S. ePassports 2Entrust Digital Signatures Help Secure More Than 18 Million U.S. ePassports 3Entrust Digital Signatures Help Secure More Than 18 Million U.S. ePassports 4Physician-scientists seek solutions to reproductive problems related to chromosomal variations 2Physician-scientists seek solutions to reproductive problems related to chromosomal variations 3
... The FastPlax Antibody is used to detect ... the surface of infected cells as early ... basis of the FastPlax Titer Kit, which ... 25-48 hours. The FastPlax Antibody ...
Alexa Fluor 647 anti-mouse IL-12 (Interleukin-12) / IL-23 (Interleukin-23) p40 25 ug...
PKC (pSer345), phospho-specific...
PE Rat anti-Hu CD267 Storage Temperature: Refrigerate(2 to 8C)...
Biology Products: